Since it became apparent that KRAS mutations are not only prognostic [34, 35] but also predictive [36, 37] of response to anti-EGFR therapy, numerous studies have investigated intra- and inter-tumor heterogeneity for KRAS status. Here, EGFR is linked to neoplasm.